MeSH D015464 - bcr-abl positive chronic myelogenous leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Idarubicin | Idarubicin | 2002-05-01 | |||
| Imatinib | Imatinib Teva | 2013-01-07 | ||||
| Cyclophosphamide | Neosar | 1993-04-29 | ||||
| Imatinib | Imatinib Teva B.V | 2017-11-15 | ||||
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 | ||
| Mylan | Busulfan | Busulfan | 2018-07-13 | |||
| Rising Pharmaceuticals | Idarubicin | Idarubicin | 2012-10-11 | |||
| Cipla | Cyclophosphamide | Cyclophosphamide | 2019-01-18 | |||
| Sandoz | Idarubicin | Idarubicin | 2011-03-29 | |||
| Cyclophosphamide | Cyclophosphamide | 2023-09-12 | ||||
| Novartis | Imatinib | Glivec | 2001-11-07 | |||
| Asciminib | Scemblix | 2022-08-25 | $301 M | Q2/22-Q2/24 | ||
| Nilotinib | Tasigna | 2007-11-19 | $1,943 M | Q2/21-Q2/24 | ||
| Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
| Interferon alfa-2b | IntronA | 2000-03-09 | ||||
| Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
| Pfizer | Bosutinib | Bosulif | 2013-03-27 | $645 M | Y2023 | |
| Idarubicin | Idamycin | 1990-09-27 | ||||
| Barr Pharmaceuticals | Hydroxyurea | Hydroxyurea | 1998-07-30 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
53%85/159
Phase 2
32%39/122
Phase 3
39%22/56
Approved: 13Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use